Verastem Oncology to Participate in Upcoming Investor Conferences - Jan 04, 2022
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:
- H.C. Wainwright BIOCONNECT Virtual Conference; the fireside chat will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. ET
- B. Riley Oncology Conference; fireside chat on Friday, January 28, 2022 at 9:30 a.m. ET
A webcast of the fireside chats will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be made available following each event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005714/en/
Source: Verastem Oncology
View this news release online at: